Weekly Market Recap: Electra Therapeutics, Orion180, and Anthropic's $2T Pre-IPO Surge

Four US IPOs priced this week, led by biotech Electra Therapeutics and insurer Orion180, while investors also got a fresh read on Anthropic's private-market value as pre-IPO derivatives markets pushed its implied valuation above $2 trillion. Here is what actually happened between September 14 and September 18, 2026, and what is next on the calendar. For the full list of upcoming and recently priced deals, see our IPO Calendar.

This Week's Debuts

• American Savings Bank of Hawaii (NYSE: ASBH) — priced September 16 at $16.00 per share, selling 7.5 million shares (all from existing stockholders) to raise about $120 million; closed its first day at $17.00, up 6.25%.
• Electra Therapeutics (Nasdaq: ETRA) — priced September 18 at $15.00, the upper half of its $14–$16 range, selling 23.3 million shares to raise roughly $350 million. The late clinical-stage biotech is developing ipsoprubart, a pan-SIRP monoclonal antibody in the registrational Phase 2/3 SURPASS trial for secondary hemophagocytic lymphohistiocytosis (sHLH).
• Orion180 Insurance Group (Nasdaq: OIG) — priced September 18 at $12.00, below its marketed $15–$17 range, selling 20 million shares to raise $240 million. The Melbourne, Florida-based insurer writes excess-and-surplus homeowners coverage concentrated in Texas, California and Florida.
• Leader's Advantage Acquisition Corp. (Nasdaq: LEDRU) — a blank-check SPAC that priced September 18 at $10.00 per unit, raising $150 million.

Fact vs. estimate: Pricing, share counts and offer prices above are confirmed figures from IPOScoop and company filings as of September 18, 2026. First-day trading results for Electra Therapeutics, Orion180 and Leader's Advantage were not yet available at the time of writing, since all three began trading only today; only American Savings Bank, which started trading September 16, has a confirmed first-day close.

The Bigger Story: Anthropic's Pre-IPO Valuation Tops $2 Trillion

Off the official calendar, the week's biggest Pre-IPO story was Anthropic. With its confidential S-1 still unpublished, perpetual futures contracts tracking Anthropic's eventual public valuation traded on Hyperliquid, the largest decentralized derivatives venue, at an implied market cap that reached an all-time high of roughly $2.36 trillion and sat near $2.15 trillion at midweek — more than double the $965 billion valuation set in Anthropic's $65 billion Series H round in May 2026. Reports point to a target IPO valuation around $2 trillion, with Goldman Sachs, JPMorgan and Morgan Stanley said to be leading an offering that could raise more than $60 billion. Market makers caution that with just single-digit millions of dollars in daily volume on these instruments, the pricing reflects genuine but thin demand rather than a reliable forecast of where shares will actually trade once the S-1 is public. Anthropic has separately moved to void any unauthorized transfers of its stock ahead of listing, including through tokenized products or special-purpose vehicles.

What's Ahead Next Week

The calendar picks back up September 23 with Bamboo Insurance Services (BMB), marketing 35 million shares at $18.00–$20.00 to raise up to $665 million — the largest deal currently on the board. The same day, Amaero (AMRO) is expected to complete a Nasdaq cross-listing at $7.06 per share (about $52.7 million). The week of September 24 brings two smaller Eddid Securities-led deals, BW Industrial Holdings (BWGC) and Web3Labs Global (MDAT), and Encore Medical (EMI) is slated to price around $15 million on September 30. See the full, continuously updated IPO Calendar for terms and dates as they firm up.

Why It Matters for Pre-IPO and Tokenized Equity Investors

This week's split verdict — a strong reception for Electra Therapeutics against a discounted price for Orion180 — shows that public investors are still pricing risk selectively even in an active IPO week, a useful signal for the broader private-to-public pipeline that Pre-IPO and tokenized equity investors track. Anthropic's perpetual futures trading above a $2 trillion implied valuation confirm there is real appetite for exposure to pre-IPO AI leaders, but the company's own move to void unauthorized token transfers is a pointed reminder that synthetic or tokenized exposure to a private company carries risks that disappear only once shares are actually registered and tradeable on a public exchange. Investors weighing tokenized pre-IPO exposure to Anthropic, OpenAI, or SpaceX should treat derivatives pricing as a sentiment gauge, not a guaranteed path to the eventual IPO price.

This material is for informational purposes only and does not constitute individual investment advice.

Sources

• IPOScoop — 2026 Pricings
• IPOScoop — IPO Calendar
• Renaissance Capital — Electra Therapeutics sets terms for $325 million IPO
• AOL (Reuters) — Orion180 Insurance prices US IPO below range, raises $240 million
• Euronews — Anthropic priced above $2 trillion as markets eagerly await IPO filing
• Crypto Briefing — Anthropic's implied valuation hits $2 trillion as tokenized trading takes off
• Yahoo Finance — American Savings Bank Announces Launch of Initial Public Offering
• Meros Research — IPO Calendar: Upcoming US IPOs This Week